Press Releases

Latest

Year-To-Date and Q3 2017 Results
9 November 2017
AstraZeneca shares scientific updates from its extensive cardiovascular, renal and metabolic diseases (CVMD) portfolio at AHA 2017
8 November 2017
AstraZeneca provides update on tralokinumab Phase III programme in severe, uncontrolled asthma
1 November 2017
US FDA approves AstraZeneca’s Calquence (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma
31 October 2017
AstraZeneca and Incyte enter clinical trial collaboration in early lung cancer
31 October 2017
AstraZeneca and MSD rapidly advance Lynparza in Japan with a second regulatory submission
23 October 2017
US FDA approves new easy-to-use, once-weekly Bydureon BCise injectable medicine for patients with type-2 diabetes
23 October 2017
US FDA accepts regulatory submission for Lynparza in metastatic breast cancer and grants Priority Review
18 October 2017
US FDA accepts supplemental Biologics License Application for Imfinzi in locally advanced unresectable non-small cell lung cancer
17 October 2017
AstraZeneca shares its comprehensive scientific approach at the World Conference on Lung Cancer 2017
16 October 2017

Can't find what you are looking for? Our Press Release archive contains all of our press releases dated before 2011 so you should be able to find just what you are looking for.

Explore archive

Contact us

Karen Birmingham

Director Global Science Media

+44 203 749 5634

Rob Skelding

Director Global Media Relations

+44 203 749 5821

Matthew Kent

Director Global Media Relations

+44 203 749 5906

Gonzalo Viña

Director Global Media Relations

+44 203 749 5916

Jacob Lund

Director External Communications, Sweden

+46 8 553 260 20

Lotta Sjösten

Manager Media Relations, Sweden

+46 8 553 271 10

US Media Team

+1 302 885 2677

Press Releases

Contact us

Subscribe

Follow us

LinkedIn